{"created":"2023-06-19T10:43:29.621791+00:00","id":3722,"links":{},"metadata":{"_buckets":{"deposit":"f88ef39b-a040-4bb2-89fe-f7eac88aa867"},"_deposit":{"created_by":11,"id":"3722","owners":[11],"pid":{"revision_id":0,"type":"depid","value":"3722"},"status":"published"},"_oai":{"id":"oai:shiga-med.repo.nii.ac.jp:00003722","sets":["19:232:233","30:196:197","30:57:269"]},"author_link":["1949","2909","12","8244","6456","6322","700","8245","561"],"item_4_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020-10-22","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageStart":"270","bibliographicVolumeNumber":"18","bibliographic_titles":[{},{"bibliographic_title":"World Journal of Surgical Oncology","bibliographic_titleLang":"en"}]}]},"item_4_creator_3":{"attribute_name":"著者別名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"窪田, 成寿"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"吉田, 哲也"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"影山, 進"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"礒野, 高敬"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"湯浅, 健"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"九嶋, 亮治"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"河内, 明宏"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"茶野, 徳宏"}],"nameIdentifiers":[{},{},{}]}]},"item_4_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background:\nAccurate prediction of the prognosis of RCC using a single biomarker is challenging due to the genetic heterogeneity of the disease. However, it is essential to develop an accurate system to allow better patient selection for optimal treatment strategies. ARL4C, ECT2, SOD2, and STEAP3 are novel molecular biomarkers identified in earlier studies as survival-related genes by comprehensive analyses of 43 primary RCC tissues and RCC cell lines. ","subitem_description_type":"Abstract"},{"subitem_description":"Methods:\nTo develop a prognostic model based on these multiple biomarkers, the expression of four biomarkers ARL4C, ECT2, SOD2, and STEAP3 in primary RCC tissue were semi-quantitatively investigated by immunohistochemical analysis in an independent cohort of 97 patients who underwent nephrectomy, and the clinical significance of these biomarkers were analyzed by survival analysis using Kaplan-Meier curves. The prognostic model was constructed by calculation of the contribution score to prognosis of each biomarker on Cox regression analysis, and its prognostic performance was validated. ","subitem_description_type":"Abstract"},{"subitem_description":"Results:\nPatients whose tumors had high expression of the individual biomarkers had shorter cancer-specific survival (CSS) from the time of primary nephrectomy. The prognostic model based on four biomarkers segregated the patients into a high- and low-risk scored group according to defined cut-off value. This approach was more robust in predicting CSS compared to each single biomarker alone in the total of 97 patients with RCC. Especially in the 36 metastatic RCC patients, our prognostic model could more accurately predict early events within 2 years of diagnosis of metastasis. In addition, high risk-scored patients with particular strong SOD2 expression had a much worse prognosis in 25 patients with metastatic RCC who were treated with molecular targeting agents. ","subitem_description_type":"Abstract"},{"subitem_description":"Conclusions:\nOur findings indicate that a prognostic model based on four novel biomarkers provides valuable data for prediction of clinical prognosis and useful information for considering the follow-up conditions and therapeutic strategies for patients with primary and metastatic RCC. ","subitem_description_type":"Abstract"}]},"item_4_description_42":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Journal Article","subitem_description_type":"Other"}]},"item_4_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"BioMed Central Ltd"}]},"item_4_relation_10":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"33092599","subitem_relation_type_select":"PMID"}}]},"item_4_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"10.1186/s12957-020-02046-9"}],"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1186/s12957-020-02046-9","subitem_relation_type_select":"DOI"}}]},"item_4_relation_13":{"attribute_name":"PMCID","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"PMC7584101"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7584101/","subitem_relation_type_select":"URI"}}]},"item_4_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© The Author(s). 2020"}]},"item_4_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"14777819","subitem_source_identifier_type":"ISSN"}]},"item_4_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"KUBOTA, Shigehisa"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"Yoshida, Tetsuya"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"KAGEYAMA, Susumu"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"ISONO, Takahiro"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"YUASA, Takeshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"YONESE, Junji"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"KUSHIMA, Ryoji"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"KAWAUCHI, Akihiro"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"CHANO, Tokuhiro"}],"nameIdentifiers":[{},{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-11-06"}],"displaytype":"detail","filename":"s12957-020-02046-9.pdf","filesize":[{"value":"4.4 MB"}],"format":"application/pdf","license_note":"This article is licensed under a Creative Commons Attribution 4.0 International License,\nwhich permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give\nappropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if\nchanges were made. The images or other third party material in this article are included in the article's Creative Commons\nlicence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons\nlicence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain\npermission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.\nThe Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the\ndata made available in this article, unless otherwise stated in a credit line to the data.","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"s12957-020-02046-9","url":"https://shiga-med.repo.nii.ac.jp/record/3722/files/s12957-020-02046-9.pdf"},"version_id":"d9f6f873-8d14-41cb-b1ad-914cd98d443f"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"ADP-ribosylation factor-like 4C (ARL4C)","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Epithelial cell transforming 2 (ECT2)","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Global transcriptome analysis","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Multiple biomarkers","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Prognostic model","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Renal cell carcinoma (RCC)","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"STEAP3 metalloreductase (STEAP3)","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Superoxide dismutase 2 (SOD2)","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"A risk stratification model based on four novel biomarkers predicts prognosis for patients with renal cell carcinoma.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"A risk stratification model based on four novel biomarkers predicts prognosis for patients with renal cell carcinoma."}]},"item_type_id":"4","owner":"11","path":["197","233","269"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-11-06"},"publish_date":"2020-11-06","publish_status":"0","recid":"3722","relation_version_is_last":true,"title":["A risk stratification model based on four novel biomarkers predicts prognosis for patients with renal cell carcinoma."],"weko_creator_id":"11","weko_shared_id":-1},"updated":"2023-06-19T11:55:36.353034+00:00"}